Abstract
Recent data suggests that heart dose independently predicts OS after RT for non-SCLC. However, to date, limited research on the impact of cardiac dose on OS of SCLC patients has been reported, with only one paper by Ni et al. (J. Thorac. Dis. 2019) exploring this in a cohort of 18 stage III SCLC patients. Moreover, further investigations are needed to determine whether heart dose is more significant than dose to other structures local to the tumour, such as the lungs or oesophagus. In this study, we investigate the impact of heart, lung and oesophageal dosimetry on the OS of SCLC patients following chemo-RT.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
